<DOC>
	<DOCNO>NCT01146574</DOCNO>
	<brief_summary>This first study hemodialysis subject anemia evaluate pharmacokinetics , safety , efficacy , tolerability , pharmacodynamics sotatercept ( ACE-011 )</brief_summary>
	<brief_title>A Phase 2a Study To Evaluate The Pharmacokinetics , Safety , Efficacy , Tolerability , And Pharmacodynamics Sotatercept ( ACE-011 ) Correction Anemia Subjects With End-stage Renal Disease Hemodialysis .</brief_title>
	<detailed_description>Part 1 : Approximately 8 subject randomize receive either single 0.1 mg/kg subcutaneous dose sotatercept match placebo 3:1 ratio Part 2 : Approximately 8 subject randomize 3 sequential dose group ( 0.3mg/kg 0.5mg/kg 0.7 mg/kg ) 3:1 ratio sotatercept placebo ( 6 subject sotatercept arm 2 placebo arm ) . A total 24-36 subject may randomize 3 dose group .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Males female ≥18 year age . Subjects hemodialysis least 12 week screen Subjects stable dose Erythrocyte Stimulating Agents product maintain Hemoglobin ( Hb ) least 6 week prior screen . 3 consecutive predialysis Hb concentration mean ≥10 ≤ 12 g/dL ( ≥100 ≤120 g/L ) screen one predialysis Hb concentration ≥8 &lt; 10 g/dL ( ≥ 80 &lt; 100 g/L ) randomization . Adequate iron status define serum transferrin saturation ≥ 20 % randomization . Non renal cause anemia . Subjects peritoneal dialysis . Systemic hematological disease High sensitivity Creactive protein &gt; 50mg/L screening . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) laboratory value &gt; 2 time upper limit normal ( ULN ) screening . Uncontrolled diabetes mellitus ( HbA1c &gt; 9 ) screening . Uncontrolled hypertension . Red Blood Count ( RBC ) transfusion within 8 week prior screen . Active serious infection history recurrent serious infection likely recur study History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational product iron product need normalize iron level subject . Subjects receive treatment another investigational drug device within 28 day prior Day 1 Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>Anemia</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Renal Anemia</keyword>
	<keyword>ESRD</keyword>
</DOC>